Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by E. J. Lipson
Ipilimumab: An Anti-Ctla-4 Antibody for Metastatic Melanoma
Clinical Cancer Research
Cancer Research
Oncology
Related publications
Comment on ‘Efficacy and Toxicity of Treatment With the Anti-Ctla-4 Antibody Ipilimumab in Patients With Metastatic Melanoma After Prior Anti-Pd-1 Therapy’
British Journal of Cancer
Cancer Research
Oncology
The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-Ctla-4 Therapy in Metastatic Melanoma From the Ipilimumab Network
PLoS ONE
Multidisciplinary
CTLA-4 Antibody Ipilimumab Negatively Affects CD4+ T-Cell Responses in Vitro
Cancer Immunology, Immunotherapy
Cancer Research
Medicine
Oncology
Allergy
Immunology
Corrigendum: Association of CTLA-4 Gene Variants With Response to Therapy and Long-Term Survival in Metastatic Melanoma Patients Treated With Ipilimumab: An Italian Melanoma Intergroup Study
Frontiers in Immunology
Allergy
Immunology
Bevacizumab Plus Ipilimumab in Patients With Metastatic Melanoma
Cancer immunology research
Cancer Research
Immunology
CTLA4 Methylation Predicts Response to Anti–PD-1 and Anti–CTLA-4 Immunotherapy in Melanoma Patients
JCI insight
Medicine
Panhypopituitarism in Metastatic Melanoma Patient Treated With Ipilimumab and Pembrolizumab
Journal of Cutaneous Immunology and Allergy
An Anti-Cd154 Domain Antibody Prolongs Graft Survival and Induces Foxp3+iTreg in the Absence and Presence of CTLA-4 Ig
American Journal of Transplantation
Transplantation
Allergy
Immunology
Pharmacology
Remitting Seronegative Symmetrical Synovitis With Pitting Edema (RS3PE) Associated With Partial Melanoma Response Under Anti-Ctla-4 and Anti-Pd-1 Combination
Arthritis and Rheumatology
Rheumatology
Allergy
Immunology
